CML vaccines as a paradigm of the specific immunotherapy of cancer
- 1 June 2000
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 14 (2) , 111-120
- https://doi.org/10.1054/blre.2000.0127
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- In vitro cytokine-primed leukaemia cells induce in vivo T cell responsiveness in chronic myeloid leukaemiaBone Marrow Transplantation, 1998
- High- and Low-Potency Ligands with Similar Affinities for the TCRImmunity, 1998
- Peptides derived from the whole sequence of BCR‐ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytesEuropean Journal of Immunology, 1997
- Cyclosporin A/alpha interferon-induced autologous graft-versus-host disease following peripheral blood stem cell transplant for chronic myeloid leukaemia: a clinico-pathological studyBone Marrow Transplantation, 1997
- Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cellsHuman Immunology, 1997
- Identification of a Graft Versus Host Disease-Associated Human Minor Histocompatibility AntigenScience, 1995
- Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia.The Journal of Experimental Medicine, 1992
- Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes.The Journal of Experimental Medicine, 1991
- Fused transcript of abl and bcr genes in chronic myelogenous leukaemiaNature, 1985
- IMMUNOTHERAPY OF CHRONIC MYELOCYTIC LEUKEMIA: EFFECTS OF DIFFERENT VACCINATION SCHEDULESAnnals of the New York Academy of Sciences, 1976